Pembrolizumab vs ipilimumab in advanced melanoma (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Source: MDLinx, August 2019

Researchers describe findings after a 5-year follow-up among participants of an open-label, multicenter, randomized, controlled, phase 3 study assessing pembrolizumab vs ipilimumab in patients with advanced melanoma. Ipilimumab-naive patients with advanced melanoma with known BRAF V600 status and up to one previous systemic therapy with Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly allocated (1:1:1) to intravenous pembrolizumab 10 mg/kg every 2 weeks or every 3 weeks or four doses of intravenous ipilimumab 3 mg/kg every 3 weeks.

read the original full article

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder